Posts Tagged ‘university hospitals case medical center’

University Hospitals Case Medical Center Remains Among the Elite in U.S. News & World Report Annual Survey

July 16, 2010

University Hospitals Case Medical Center (UHCMC) has again ranked among the elite in the latest U.S. News & World Report hospital rankings.  In this year’s survey, UHCMC ranked seven clinical specialties in the top 50 for hospitals and health systems nationwide.

Top among clinical departments at UHCMC, the Department of Medicine again contributed four of the specialties – Gastroenterology (28), Geriatrics (28), Cancer (34), and Pulmonology (42). This contribution by the Department of Medicine figured significantly into UHCMC joining only 152 other hospitals, or the top 3% of the nation’s 5,000 eligible healthcare organizations.

“This consistent level of excellence in compassionate, cost-effective patient care is a testament to the quality and dedication of the full time faculty in the Department of Medicine and to the leadership of our organizations.”

Richard A. Walsh, MD, Chairman, Department of Medicine

Advertisements

Angiotensin-Receptor Blockades (ARBs) Found to Raise Risk of Cancer

July 9, 2010

Dr. Daniel Simon M.D., Division Chief of Cardiovascular Medicine and Director of HM-Heart and Vascular Institute at UHCMC; Dr. James Fang M.D., Section Chief of Heart Failure and Medical Director of Heart Transplantation at UHCMC; IIke Sipahi M.D., Associate Director of Heart Failure & Transplantation at UHCMC at the Harrington-McLaughlin Heart & Vascular Institute of UHCMC researched the effects of Angiotensin-Receptor Blockers (ARBs) on the risk of cancer.

ARBs are a widely utilized drug class used for treatment of hypertension, heart failure, diabetic nephropathy, and recently, for cardiovascular risk reduction.

Randomized controlled trials of ARBs with a follow-up of at least 1 year, and enrolling at least 100 patients were included in this meta-analysis. Information on new cancer development (first diagnosis) was available for 61,590 patients from five trials. Cancer data on common types of solid organ cancers such as lung and prostate cancer were available for 68,402 patients from five trials, and data on cancer deaths were available for 93,515 patients from eight trials.

The meta-analysis showed that patients randomly assigned to receive ARBs had a significantly increased risk of new cancer occurrence compared with patients in control groups (7.2%vs 6.0%). Specifically, the risk of lung cancer was increased by 25%, which was also statistically significant.

“We have found the risk of new cancers was increased with these medications by 8-11 percent.  Most importantly, risk of lung cancer was increased by 25 percent,” said Dr. Sipahi. Although there was no statistically significant excess in cancer deaths (1.8% with ARBs vs 1.6% with control) the investigators pointed out that the average duration of follow-up of 4 years may be too short to capture cancer deaths.

“In medicine, physicians must balance the benefits and risks of all drug and device therapies.  We recommend that patients discuss the findings of this study with their physicians since ARBs are effective agents in the treatment of high blood pressure and heart failure,” said Dr. Simon.

They conclude that because of the limited data, it is not possible to draw conclusions about the exact risk of cancer associated with each individual ARB on the market, but they stated that their findings need further investigation.

In response to this publication from Case Western Reserve University, the European Medicines Agency (EMA) of the European Union announced that they started an investigation about the possible cancer risk of ARBs.

“This is the first time an association between ARBs and cancer development is suggested,” Dr. Sipahi continued. “While our findings are robust, they need to be replicated in other studies before they can be considered as definitive.”

The US Food and Drug Administration has not made any statement regarding this issue yet.

Correlation Between Methicillin-Resistant Staphylococcus Aureus and Cystic Fibrosis Proven

July 9, 2010

Led by Dr. Elliott Dasenbrook MD MHS, Associate Director of The Adult Cystic Fibrosis Program, a UHCMC team in the Division of Pulmonary, Critical Care, and Sleep Medicine have published the findings from a major study about cystic fibrosis (CF) survival rates in the June 16 issue of JAMA.

Specifically, the study observed patients with CF who had methicillin-resistant Staphylococcus aureus (MRSA) detected in their respiratory tract.

The team composed a study with 19,833 CF patients across the nation between ages 6 and 45.  Times until death after diagnosis with MRSA were recorded in order to compare survival between CF patients with and without respiratory tract MRSA.

The unadjusted mortality rate was 18.3 deaths (95% confidence interval [CI], 17.5-19.1) per 1000 patient-years in patients without MRSA and 27.7 deaths (95% CI, 25.3-30.4) per 1000 patient-years in those with MRSA.  The team showed that there is a significantly higher rate of death in CF in people that have MRSA.

“Our study findings may prompt many doctors to reconsider how they care for CF patients,” says Dr. Dasenbrook. He adds, “Until now, some CF doctors weren’t aggressively treating patients with MRSA.  Doctors often viewed MRSA to not be as important as other respiratory-tract infections. With our study findings, treatment patterns may changes as the risk of death is 1.3 times greater for CF patients with MRSA.”

Cardiologists discover cancer risks in group of blood pressure medications

June 24, 2010

University Hospitals Case Medical Center cardiologists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers (ARBs).

This class of drugs is used by millions of patients not only for high blood pressure but also for heart failure, cardiovascular risk reduction and diabetic kidney disease.

University Hospitals Harrington-McLaughlin Heart & Vascular Institute’s Drs. Ilke Sipahi, Daniel I. Simon and James C. Fang recently completed a meta-analysis of over 60,000 patients randomly assigned to take either an ARB or a control medication. Their findings are published online today at The Lancet Oncology.

The researchers found that patients randomized to ARBs has “significantly increased risk of new cancer” compared to control patients.

“We have found the risk of new cancers was increased with these medications by 8-11 percent,” said Dr. Ilke Sipahi, associate director of heart failure and transplantation and assistant professor at Case Western Reserve University School of Medicine. “Most importantly, risk of lung cancer was increased by 25 percent.”

However, the research did not establish any link between ARBs and other types of cancer such breast cancer.

“This is the first time an association between ARBs and cancer development is suggested,” Dr. Sipahi continued. “While our findings are robust, they need to be replicated in other studies before they can be considered as definitive.”

Before this study, there were no major safety concerns with ARBs except for their use in pregnancy and in patients with chronic kidney or blockages of kidney arteries. Interestingly, previous animal studies with ARBs have been negative for cancer development.

“In medicine, physicians must balance the benefits and risks of all drug and device therapies,” said Dr. Daniel Simon, director of the Harrington-McLaughlin Heart & Vascular Institute at University Hospitals Case Medical Center and professor at Case Western Reserve University School of Medicine. “We recommend that patients discuss the findings of this study with their physicians since ARBs are effective agents in the treatment of high blood pressure and heart failure. Meta-analyses are a powerful tool to look at low frequency safety signals, but require confirmation with other approaches, such as large national health and managed care registries.”

UH received Top Health System Award

June 24, 2010

University Hospitals named one of the Top 10 Health Systems in U.S.

For the second consecutive year, University Hospitals (UH) has been named one of the top 10 health systems in the United States based on clinical performance by Thomson Reuters, a leading business and professional information organization.

UH and the other top 10 systems outperformed their peers by a wide margin. They provided better care, followed standards of care more closely, saved more lives, had fewer patient complications, and made fewer patient safety errors.

The list was compiled in a study conducted by researchers from the Thomson Reuters 100 Top Hospitals®. They analyzed the quality and efficiency of 255 health systems based on eight metrics that gauge clinical quality and efficiency: mortality, medical complications, patient safety, average length of stay, 30-day mortality rate, 30-day readmission rate, adherence to clinical standards of care (evidence-based core measures published by the Centers for Medicare and Medicaid Services), and HCAHPS patient survey score (part of a national initiative sponsored by the U.S. Department of Health and Human Services to measure the quality of care in hospitals).

Thomson Reuters rankings are available at www.thomsonreuters.com.

Philips Healthcare, State of Ohio Announce Global Advanced Imaging Innovation Center

June 4, 2010

A $33.5 million commitment by Philips Healthcare and a $5 million Third Frontier grant from the state of Ohio will provide researchers at Case Western Reserve University, University Hospitals Case Medical Center, and Philips an opportunity to create medical imaging systems that will detect disease far earlier and be safer for patients than current methods.

The company and state announced the creation of the Global Advanced Imaging Innovation Center, to be housed at the University Hospitals Case Medical Center campus, at the same press conference where Gov. Ted Strickland designated Cleveland’s Health-Tech Corridor a state Hub of Innovation and Opportunity yesterday.

The corridor, created by the non-profit BioEnterprise and the economic-development corporation MidTown Cleveland, runs from downtown to University Circle. It includes Case Western Reserve, University Hospitals Case Medical Center (UHCMC), the Cleveland Clinic, Cleveland State University, Louis Stokes Cleveland VA Medical Center, and St. Vincent Charity Medical Center along with 75 biomedical companies, 45 technology companies and seven business incubators.

“We are pleased that the State of Ohio has awarded Ohio Third Frontier funding to our project,” said Jay Mazelsky, Senior Vice President and General Manager for Computed Tomography and Nuclear Medicine at Philips Healthcare. The company, which employs 1,100 in Highland Heights, has committed more than $6 million annually for five years, to the project.

“The goals of this center will be to provide strategic research, development and clinical validation for advanced imaging technologies, further developing our presence in northeast Ohio and building on our existing partnerships with Case Western Reserve University and University Hospitals.”

Using Phillip’s latest imagers, physicians and researchers from CWRU will help develop a variety of medical imaging technologies expected to enable doctors to see into the body’s molecules and atoms, revealing anatomical and functional information currently unattainable. They will test and improve imagers to provide for earlier diagnostics and better tracking of disease progression while increasing safety and comfort to patients.

Case Western Reserve is the lead agency for the state’s $5 million grant supporting the effort.

“This award is emblematic of the way that members of this corridor work together to achieve more than any organization could alone,” Case Western Reserve President Barbara R. Snyder said of the Third Frontier grant.

Snyder recounted the success CWRU has had in generating business and collaborating with hospitals and industry. As a result of professors’ research, the university has launched 24 companies since 2001; reaped $16.3 million in licensing revenue last year alone; and won an average of $385 million in state, federal and other grants during the last five years. In 2007, Case Western Reserve became lead agency, partnering with University Hospitals and Cleveland Clinic, on a $64 million Clinical and Translational Science Award – the largest single grant the National Institutes of Health has made in Northeast Ohio.

The announcements were made at the BioEnterprise building, in a room packed with Health-Tech Corridor boosters and members, including Cleveland Mayor Frank Jackson, Cuyahoga County Commissioner Tim Hagan, Cleveland Foundation President Ronn Richard and officials from UHCMC, Cleveland State University, the Cleveland Clinic and media.

The hub overlays the corridor. The new state designation comes with a $250,000 grant and gives research and development within the hub priority for future state grants.

Baiju Shah, president of BioEnterprise, said the Dutch-owned Philips could have chosen any location worldwide, but, “Their decision to locate their Center within the Cleveland Health-Tech Corridor is an example of what can happen when public entities led by the State of Ohio, private institutions, philanthropy and nonprofits collaborate.”

University Hospitals Case Medical Center Earns Prestigious National Award for Excellence in Delivering High-Quality Care

June 3, 2010

University Hospitals (UH) Case Medical Center is one of five academic medical centers in the nation to receive the 2009 Quality Leadership Award from the University HealthSystem Consortium (UHC). The prestigious award is given to teaching hospitals that demonstrate excellence in delivering high-quality care, as measured by the UHC Quality and Accountability Study conducted annually since 2005.

This year, 93 member hospitals were ranked by UHC, a national organization representing more than 90 percent of the nation’s nonprofit academic medical centers. UHC’s distinctive study measured hospitals’ performance using the Institute of Medicine’s six domains of care—safety, timeliness, effectiveness, efficiency, equity, and patient centeredness.

“We are proud of this extraordinary achievement which reflects University Hospitals’ ongoing commitment to quality and safety for our patients,” said Fred C. Rothstein, M.D., President of UH Case Medical Center. “This is an exceptional recognition when you consider that academic medical centers across the country participated in the survey.   We are pleased that the excellence of our health care providers and staff was recognized by this prestigious organization of peer institutions.”

“National recognition is well deserved for these organizations that have distinguished themselves as high-performing organizations in a complex environment. I salute the top performers and extend congratulations to all academic medical center leaders and employees who daily demonstrate a passion for improving patient care and operational effectiveness,” said UHC President and Chief Executive Officer Irene M. Thompson.

UHC examined data provided by member hospitals through its comparative clinical, operational, and core measures data bases and reviewed additional source data from the publicly reported Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey.

Other hospitals recognized this year in addition to UH Case Medical Center:

  • Methodist Hospital—A Clarian Health Partner, Indianapolis
  • Rush University Medical Center, Chicago
  • University Medical Center, Tucson
  • The University of Kansas Hospital Authority, Kansas City

“As an organization, UHC is committed to improving members’ performance. Through this study, we are able to determine what structures and practices are associated with excellent performance across an AMC,” said Mark Keroack, M.D., M.P.H., Chief Medical Officer and Vice President of the UHC Clinical Practice Advancement Center. Dr. Keroack, with others at UHC, developed the study approach and has conducted several organizational development workshops for UHC members across the country.

He is the lead author of “Organizational Factors Associated With High Performance in Quality and Safety in Academic Medical Centers,” published in the December 2007 issue of Academic Medicine. The critical success factors first identified in that study are a shared sense of purpose throughout the organization, leadership style, an accountability system, a focus on results, and a collaborative culture.

Good Morning America visits new heart imaging device in Cleveland

May 27, 2010

Dr. Marco Costa found a second blocked artery in Mack Bailey’s heart — and demonstrated to a Good Morning America audience the first vascular-imaging technology based on optical coherence tomography (OCT) — at the same time Thursday.

Costa is an interventional cardiologist and director of the cardiovascular research institute at University Hospitals Case Medical Center in Cleveland, Ohio. Bailey is a 60-year-old Clevelander with had a heart attack and is being treated by Costa.

Both agreed to be filmed and interviewed by the NBC morning news show because University Hospitals is the first — and so far only — hospital to use the C7-XR Imaging System and accompanying C7 Dragonfly Imaging Catheter made by LightLab Imaging Inc. during patient heart procedures.

While using the technology to place a stent in one of Bailey’s heart arteries, Costa found a second blocked artery that had not shown up on images of Bailey’s heart. Costa ended up placing two stents, that day.

“If he had gone home this weekend without having this procedure today, he would have gone home with a very nice, well-placed stent in the vessel that did not cause the heart attack,” Costa said during the Good Morning America segment.

The LightLab system uses near-infrared light to produce high-resolution, real-time images that are better and faster than images produced by competing ultrasound technology. The system recently was approved for sale by the Food and Drug Administration. UH Case Medical Center was the core laboratory on the FDA approval study and analyzed the study’s results, according to the Case Western Reserve University School of Medicine blog.

Impotence plus heart disease ups death risk – Dr. Sahil Parikh discusses the study

May 27, 2010

Reuters Report ::

Men with heart disease who also have erectile dysfunction die sooner than men who do not seek treatment for impotence, researchers reported on Monday.

They found that men who had both conditions were twice as likely to die from any cause and twice as likely to have a heart attack than men with heart disease alone.

The researchers expressed concern that using drugs such as Pfizer’s Viagra or Eli Lilly’s Cialis to treat erectile dysfunction could mask the symptoms that point to widespread heart and artery disease and said men complaining of impotence should be checked by a cardiologist.

“Erectile dysfunction is something that regularly should be addressed in the medical history of patients; it might be a symptom of early atherosclerosis,” Dr. Michael Bohm of the University of Saarland in Germany, who led the study, said in a statement.

His team studied 1,519 men in 13 countries taking part in some larger studies of various heart disease treatments. As part of the study the men were also asked about erectile dysfunction.

More than half of them, 55 percent, did, Bohm’s team said in a report published in the journal Circulation and also presented at a meeting of the American College of Cardiology.

During the two years of the study, 11.3 percent of the patients who reported erectile dysfunction died, compared to 5.6 percent of those with mild or no impotence problems.

“It has long been known that erectile dysfunction is a marker for cardiovascular disease,” said Dr. Sahil Parikh at University Hospitals Case Medical Center in Cleveland, Ohio, who was not involved in the study.

The first impotence drug, Pfizer’s Viagra, known generically as sildenafil, was at first developed to lower blood pressure, he said.

“They realized it had this other effect, which patients quite enjoyed,” Parikh said in a telephone interview.

HAPPY SIDE-EFFECT

Viagra and rival drugs such as Eli Lilly’s Cialis and Bayer AG’s BAYG.DE Levitra all work by increasing blood flow.

“In order to have proper erectile function, you have to have adequate blood flow to the genitals. If you have atherosclerosis, whether in the arteries on the neck, which can cause stroke, or the arteries of the heart, which can cause heart attack … it is the same disease.”

But while the erectile dysfunction drugs help blood flow all over the body, they do not treat the underlying hardening and narrowing in the arteries that is causing the problem.

“If patients have erectile dysfunction, we have to be very aggressive about screening and treating them for heart disease,” Parikh said.

When Viagra came onto the market, many health experts welcomed it as a way to get men who might otherwise neglect their health to go to a doctor. But Bohm and Parikh both agreed that patients — and their doctors — need to look hard at the hearts of men with erectile dysfunction.

“Men with ED going to a general practitioner or a urologist need to be referred for a cardiology workup to determine existing cardiovascular disease and proper treatment,” Bohm said.

“The medication works and the patient doesn’t show up any more,” he added. “These men are being treated for the ED, but not the underlying cardiovascular disease.”

The drugs are wildly popular. Viagra alone had sales of nearly $2 billion in 2009.